![](https://endpts.com/wp-content/uploads/2017/03/protocols-endpoints-news.jpg)
Tyme flops on cancer drug data; Lilly IND filing triggers $8M payment to partner Zymeworks
→ Tyme Technologies on Friday touted “substantially improved survival benefit” from its experimental drug SM-88 in a single arm study in advanced pancreatic cancer patients …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.